Company Profile

Coronis Partners is a leading Israeli Investment House specializing in the full range of investment banking activities to the life science sector. The Coronis team carry out extensive due diligence on potential investments and look for the key criteria of a balance of scientific excellence, top quality management and a proven business model. The success of these investments has been proven by four of the six portfolio investee companies raising funds on public markets during 2007.
News
Bayer CropScience and Evogene enter a multi-year collaboration for rice yield improvement
Bayer CropScience AG and Evogene Ltd. announced a three-year collaboration focused on increasing rice productivity and yield.
Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
MicroRNA-based Molecular Diagnostics to Mark Prometheus' Entry into Oncology Market; Rosetta to Receive Milestones and Research and Development Funding plus Future Royalties
Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
First-Ever Study, Showing In-Vivo Systemic Administration of a MicroRNA Therapeutic in Liver Cancer, With a Two-Fold Decrease in Tumor-Mass and a Dramatic Suppression of the Targeted MicroRNA May Benefit Over 19,000 Liver Cancer Patients Annually in the US; 5-Year Survival Under 10%
Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic;
Identified Candidate MicroRNA Biomarkers in Serum.Initial Data Show two microRNAs Accurately Differentiate Colorectal Cancer Patients From Healthy Individuals, in a Study of 49 Patients and 79 Controls with 91% sensitivity and 72% specificity.
Evogene and Biogemma Show Increased Corn Yield in Field Trials
Corn Containing Evogene Discovered Genes Show Significant Yield Increases under Both Normal and Drought Conditions
MODIGENE ANNOUNCES POSITIVE RESULTS OF PILOT TOXICITY
Single Injection in Primates Containing 1,000-Times the Dosage Recommended for Humans Shows No Adverse Effects. Half-Life and AUC Support the Potential for Weekly or Bi-Monthly Dosing Frequency.
Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
This is Rosetta Genomics' First Distribution Agreement, Since it Introduced its Tests in December 2008 The MiRview(TM) Tests Leverage Proprietary Microrna Technology Developed by Rosetta Genomics, and Measure The Expression Level of Specific Microrna Biomarkers in the Tumor Sample
Rosetta Genomics Announces Commercial Availability of its Second MicroRNA-Based Diagnostic Test - miRview(TM) mets
Rosetta Genomics, Ltd. announced today the commercial availability of its second diagnostic test, miRview(TM) mets. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia.
Modigene Platform Validated in Independent Phase III Trial of CTP Technology
Validates the Clinical Utility of Modigene's CTP Technology for Extending the Duration of Action of Therapeutic Proteins
Portfolio
בניית אתריםWeb Building